Skip to main content
Genome Announcements logoLink to Genome Announcements
. 2017 Jan 5;5(1):e01435-16. doi: 10.1128/genomeA.01435-16

Whole-Genome Sequences and Classification of Streptococcus agalactiae Strains Isolated from Laboratory-Reared Long-Evans Rats (Rattus norvegicus)

C Bodi Winn 1, J Dzink-Fox 1, Y Feng 1, Z Shen 1, V Bakthavatchalu 1, J G Fox 1,
PMCID: PMC5255911  PMID: 28057750

ABSTRACT

In collaboration with the CDC’s Streptococcus Laboratory, we report here the whole-genome sequences of seven Streptococcus agalactiae bacteria isolated from laboratory-reared Long-Evans rats. Four of the S. agalactiae isolates were associated with morbidity accompanied by endocarditis, metritis, and fatal septicemia, providing an opportunity for comparative genomic analysis of this opportunistic pathogen.

GENOME ANNOUNCEMENT

Streptococcus agalactiae, or group B streptococcus (GBS), is a Gram-positive opportunistic pathogen that commonly inhabits the gastrointestinal and urogenital tract of humans. It is the leading cause of neonatal septicemia and meningitis, and it is also known to cause disease in animals, including meningoencephalitis in fish, mastitis in cattle, and invasive infection in laboratory rodents (16). There is high suspicion that GBS is a zoonotic pathogen, and despite close genotypic relationships observed between different species’ isolates, direct transmission has not been reported (79). In this report, we announce the whole-genome sequences of seven GBS isolates obtained from a colony of laboratory-reared Long-Evans rats that experienced two cases of polymicrobial sepsis associated with GBS infection in two gravid female rats; two isolates were obtained from resected cardiac tissue and blood in the first case, and two isolates were obtained from cardiac tissue and fetus from the second case. An additional three asymptomatic male rats’ GBS isolates were cultured from the nares. Isolates were 16S rRNA sequenced and submitted to the CDC’s Streptococcus Laboratory for whole-genome sequencing.

The CDC’s Streptococcus Laboratory tracks cases of GBS invasive disease through their Active Bacterial Core surveillance (ABCs). After receipt of isolates, genomic DNA for short-read whole-genome sequencing was extracted manually using a modified QIAamp DNA minikit protocol (Qiagen). Nucleic acid concentration was quantified by an Invitrogen Qubit assay, and samples were sheared using a Covaris M220 ultrasonicator programmed to generate 500-bp fragments. Libraries were constructed using TruSeq DNA PCR-free high-throughput (HT) library preparation kit with 96 dual indexes and quantified by a Kapa quantitative PCR (qPCR) library quantification method. Genomes were sequenced by Illumina NGS technology using MiSeq version 2 500-cycle kit. Genomes were annotated using Rapid Annotations using Technology toolkit (RASTtk) (10, 11) (http://rast.nmpdr.org/rast.cgi).

Strains underwent the following analyses: (i) multilocus sequence typing (MLST; http://pubmlst.org/sagalactiae) (12), (ii) serotyping (13), (iii) detection of resistance genes with ResFinder (14) and the Comprehensive Antibiotic Resistance Database (CARD) (15), (iv) virulence factors (VFDB; http://www.mgc.ac.cn/VFs/) (16), and (v) antimicrobial susceptibility testing by a microdilution broth method.

MLST analysis and serotyping assigned all GBS strains except strain 195-16-B-RAT to serotype Ib, sequence type 12 (ST12) (13, 17). Strain 195-16-B-RAT is serotype V, ST1. Both serotype-sequence types are well-represented among human invasive isolates documented in the 2015 ABCs (unpublished data). Isolates were susceptible to ampicillin (≤0.25 μg/ml), ceftriaxone (≤0.5 μg/ml), erythromycin (≤0.25 μg/ml), and clindamycin (≤0.25 μg/ml) but resistant to tetracycline (>8 μg/ml). Strains were intermediate resistant to enrofloxacin (≤0.5 μg/ml), a commonly used fluoroquinolone in veterinary medicine (18, 19). Strain 195-16-B-RAT had a mutation detected in the ermA gene, denoting resistance to erythromycin. This may be due to inducible expression of the resistance-causing methylase enzyme, which leads to different phenotypes (20). All isolates had tet(M), associated with tetracycline resistance. The virulence factors identified were β-hemolysin/cytolysin (cylE), CAMP factor (cfa/cfb), hyaluronate lyase (hylB), C5a peptidase (scpB), pili (pilA, pilB, pilC), sortases (srtC3, srtC4), and Fg-binding surface protein A and B (fbsA and fbsB).

Accession number(s).

The whole-genome sequences of the seven S. agalactiae strains have been deposited at DDBL/EMBL/GenBank under the accession numbers provided in Table 1.

TABLE 1 .

Genomic characteristics of rat Streptococcus agalactiae strains

S. agalactiae strain GenBank accession no. Origin of rat isolates Presence of clinical disease Genome size (bp) No. of contigs Fold coverage G+C content (%) No. of protein-coding sequences No. of RNA sequences
195-16-B-RAT MJHP00000000 Nares No 2,134,553 22 50 35.2 2,146 56
196-16-B-RAT MJHQ00000000 Blood Yes 2,060,190 41 50 35.1 2,064 61
197-16-B-RAT MJHR00000000 Cardiac lesion Yes 2,065,096 35 50 35.1 2,072 61
198-16-B-RAT MJHS00000000 Nares No 2,060,782 38 50 35.1 2,078 65
199-16-B-RAT MJHT00000000 Nares No 2,074,289 37 50 35.1 2,080 68
200-16-B-RAT MJHU00000000 Cardiac lesion Yes 2,068,751 37 100 35.1 2,084 76
201-16-B-RAT MJHV00000000 Fetus Yes 2,063,718 35 100 35.1 2,082 70

ACKNOWLEDGMENTS

We thank Bernard Beall, Sopio Chochua, and Benjamin Metcalf at the CDC’s Streptococcus Laboratory for whole-genome sequencing, technical support, and collaboration. We thank Anthony Mannion for technical guidance. We thank Alyssa Pappa for her excellent assistance. We also thank Michael Esmail, Lauren Richey, and Scott Perkins for their contributions and support.

This work was supported in part by NIH grants T32-OD010978 (J.G.F.) and P30-ES002109 (J.G.F.).

Footnotes

Citation Bodi Winn C, Dzink-Fox J, Feng Y, Shen Z, Bakthavatchalu V, Fox JG. 2017. Whole-genome sequences and classification of Streptococcus agalactiae strains isolated from laboratory-reared Long-Evans rats (Rattus norvegicus). Genome Announc 5:e01435-16. https://doi.org/10.1128/genomeA.01435-16.

REFERENCES

  • 1.Verani JR, McGee L, Schrag SJ. 2010. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep 59:1–32. [PubMed] [Google Scholar]
  • 2.Liu G, Zhang W, Lu C. 2012. Complete genome sequence of Streptococcus agalactiae GD201008 -001, isolated in China from tilapia with meningoencephalitis. J Bacteriol 194:6653. doi: 10.1128/JB.01788-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Schenkman DI, Rahija RJ, Klingenberger KL, Elliott JA, Richter CB. 1994. Outbreak of group B streptococcal meningoencephalitis in athymic mice. Lab Anim Sci 44:639–641. [PubMed] [Google Scholar]
  • 4.Keefe GP. 1997. Streptococcus agalactiae mastitis: a review. Can Vet J 38:429–437. [PMC free article] [PubMed] [Google Scholar]
  • 5.Shuster KA, Hish GA, Selles LA, Chowdhury MA, Wiggins RC, Dysko RC, Bergin IL. 2013. Naturally occurring disseminated group B streptococcus infections in postnatal rats. Comp Med 63:55–61. [PMC free article] [PubMed] [Google Scholar]
  • 6.Geistfeld JG, Weisbroth SH, Jansen EA, Kumpfmiller D. 1998. Epizootic of group B Streptococcus agalactiae serotype V in DBA/2 mice. Lab Anim Sci 48:29–33. [PubMed] [Google Scholar]
  • 7.Manning SD, Springman AC, Million AD, Milton NR, McNamara SE, Somsel PA, Bartlett P, Davies HD. 2010. Association of group B streptococcus colonization and bovine exposure: A prospective cross-sectional cohort study. PLoS One 5:e8795. doi: 10.1371/journal.pone.0008795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Delannoy CMJ, Crumlish M, Fontaine MC, Pollock J, Foster G, Dagleish MP, Turnbull JF, Zadoks RN. 2013. Human Streptococcus agalactiae strains in aquatic mammals and fish. BMC Microbiol 13:41. doi: 10.1186/1471-2180-13-41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lämmler C, Abdulmawjood A, Weiß R. 1998. Properties of serological group B streptococci of dog, cat and monkey origin. Zentralbl Vet B 45:561–566. doi: 10.1111/j.1439-0450.1998.tb00827.x. [DOI] [PubMed] [Google Scholar]
  • 10.Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: rapid annotations using subsystems technology. BMC Genomics 9:75. doi: 10.1186/1471-2164-9-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek R, Parrello B, Pusch GD, Shukla M, Thomason JA, Stevens R, Vonstein V, Wattam AR, Xia F. 2015. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci Rep 5:8365. doi: 10.1038/srep08365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Moltó-García B, Liébana-Martos Mdel C, Cuadros-Moronta E, Rodríguez-Granger J, Sampedro-Martínez A, Rosa-Fraile M, Gutierrez-Fernández J, Puertas-Priet A, Navarro-Marí JM. 2016. Molecular characterization and antimicrobial susceptibility of hemolytic Streptococcus agalactiae from post-menopausal women. Maturitas 85:5–10. doi: 10.1016/j.maturitas.2015.11.007. [DOI] [PubMed] [Google Scholar]
  • 13.Sheppard AE, Vaughan A, Jones N, Turner P, Turner C, Efstratiou A, Patel D, Modernising Medical Microbiology Informatics Group , Walker AS, Berkley JA, Crook DW, Seale AC. Capsular typing method for Streptococcus agalactiae using whole genome sequence data. J Clin Microbiol 54:1388–1390. doi: 10.1128/JCM.03142-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kleinheinz KA, Joensen KG, Larsen MV. 2014. Applying the ResFinder and VirulenceFinder Web-services for easy identification of acquired antibiotic resistance and E. coli virulence genes in bacteriophage and prophage nucleotide sequences. Bacteriophage 4:e27943. doi: 10.4161/bact.27943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M, Mulvey MR, O’Brien JS, Pawlowski AC, Piddock LJV, Spanogiannopoulos P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright GD. 2013. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother 57:3348–3357. doi: 10.1128/AAC.00419-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, Jin Q. 2005. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res 33:D325–D328. doi: 10.1093/nar/gki008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Jones N, Bohnsack JF, Takahashi S, Oliver KA, Chan MS, Kunst F, Glaser P, Rusniok C, Crook DWM, Harding RM, Bisharat N, Spratt BG. 2003. Multilocus sequence typing system for group B streptococcus. J Clin Microbiol 41:2530–2536. doi: 10.1128/JCM.41.6.2530-2536.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Clinical and Laboratory Standards Institute (CLSI) 2013. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard, 4th ed CLSI document VET01-A4. Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
  • 19.Clinical and Laboratory Standards Institute (CLSI) 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
  • 20.Leclercq R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 34:482–492. doi: 10.1086/324626. [DOI] [PubMed] [Google Scholar]

Articles from Genome Announcements are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES